Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.
|Articles|May 9, 2011
Intraperitoneal Struggles in Ovarian Cancer Treatments
Author(s)Fiona McCaughan, RN, MS
Oncology Nurse Fiona McCaughan on Struggles Facing Intraperitoneal Ovarian Cancer Treatments
Advertisement
Fiona McCaughan, RN, MS, OCN, Hematology Oncology Nurse at Winchester Hospital in Stoughton, MA on Struggles Facing Intraperitoneal Ovarian Cancer Treatments
Advertisement
Related to this article
As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.
Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.
Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.
At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
2
Inside an APP-Led Outpatient Clinic for Bispecific Step-Up Dosing
3
AYA Needs Navigation Trial Meets Most Fidelity Targets at Interim Look
4
Childhood Leukemia Treatment Disrupts Work, Finances for Most Families
5